Side-by-side comparison of mechanisms, dosing, interactions, and stacking potential.
| Adrafinil | Coluracetam | |
|---|---|---|
| Category | Nootropics | Nootropics |
| Standard Dose | 300-600 mg once daily (for educational context — unregulated prodrug of a prescription medication) | 20-80 mg/day divided into 2-3 doses |
| Timing | Early morning on an empty stomach for faster hepatic conversion. Onset delayed 60-90 minutes. Avoid afternoon/evening dosing due to long effective duration. | Morning and early afternoon. Sublingual administration may provide faster onset. With or without food. |
| Cycle Duration | Short-term or intermittent use strongly preferred. Avoid continuous daily use exceeding 3 months without liver function monitoring. | Cycles of 4-8 weeks on, 2-4 weeks off |
| Evidence Level | moderate_human | animal_plus_anecdotal |
Inactive prodrug that is hepatically metabolized to modafinil (via hepatic amidase enzymes) and its inactive acid metabolite modafinilic acid. The active metabolite modafinil then exerts its effects as a DAT inhibitor with downstream orexinergic, histaminergic, and noradrenergic activation. Conversion is incomplete — approximately 33-50% of adrafinil is converted to modafinil, with the remainder forming inactive metabolites. The hepatic first-pass metabolism means onset is delayed (60-90 minutes vs. 30-60 minutes for modafinil).
300-600 mg once daily (for educational context — unregulated prodrug of a prescription medication)
Early morning on an empty stomach for faster hepatic conversion. Onset delayed 60-90 minutes. Avoid afternoon/evening dosing due to long effective duration.
Short-term or intermittent use strongly preferred. Avoid continuous daily use exceeding 3 months without liver function monitoring.
Enhances high-affinity choline uptake (HACU) via a unique mechanism distinct from other racetams — it increases HACU even in damaged cholinergic neurons, suggesting a choline uptake enhancement rather than mere stimulation. This HACU enhancement persists even after the compound has been cleared, indicating a lasting modification of choline transporter activity. Also shows affinity for AMPA receptors.
20-80 mg/day divided into 2-3 doses
Morning and early afternoon. Sublingual administration may provide faster onset. With or without food.
Cycles of 4-8 weeks on, 2-4 weeks off
Take our free assessment to get personalized recommendations based on your health goals, current stack, and biomarkers.
Get Your Free Protocol →or take the assessment →